{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:15:38Z","timestamp":1761059738019},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.remn.2014.04.004","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T15:01:09Z","timestamp":1400857269000},"page":"346-351","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["El regadenos\u00f3n como nuevo agente de estr\u00e9s para la adquisici\u00f3n de im\u00e1genes SPECT de perfusi\u00f3n mioc\u00e1rdica. Experiencia inicial en Holanda"],"prefix":"10.1016","volume":"33","author":[{"given":"P.L.","family":"Jager","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Buiting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mouden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.J.","family":"Oostdijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Knollema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2014.04.004_bib0005","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00259-005-1779-y","article-title":"EANM\/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology","volume":"32","author":"Hesse","year":"2005","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.remn.2014.04.004_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90474-2","article-title":"Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. The GE SPECT Multicenter Adenosine Study Group","volume":"19","author":"Gupta","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0015","unstructured":"Arlington Medical Resources. Market analysis myocardial perfusion scintigraphy 2006. [consultado 8 May 2014]. Disponible en: www.amr-data.com"},{"key":"10.1016\/j.remn.2014.04.004_bib0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: A new myocardial stress agent","volume":"54","author":"Al-Jaroudi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0025","unstructured":"Rapiscan (regadenoson). Summary of Product Characteristics, RPS EU, London."},{"key":"10.1016\/j.remn.2014.04.004_bib0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","article-title":"Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind,placebo-controlled trial (RegCOPD trial)","volume":"15","author":"Thomas","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0040","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jcmg.2009.04.011","article-title":"Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial","volume":"2","author":"Mahmarian","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.remn.2014.04.004_bib0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12350-010-9229-z","article-title":"Lessons from regadenoson and low-level treadmill\/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients","volume":"17","author":"Kwon","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0050","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00259-011-1853-6","article-title":"Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET","volume":"38","author":"Goudarzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.remn.2014.04.004_bib0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","article-title":"Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Leaker","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","article-title":"A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease","volume":"19","author":"Prenner","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10554-011-0003-3","article-title":"Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients","volume":"28","author":"Husain","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.remn.2014.04.004_bib0070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00259-012-2296-4","article-title":"Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response","volume":"40","author":"Aljaroudi","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remn.2014.04.004_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12350-012-9641-7","article-title":"A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: A randomized controlled trial","volume":"20","author":"Parker","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12350-012-9533-x","article-title":"Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. \u00abThe ASSUAGE trial\u00bb","volume":"19","author":"Doukky","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12350-011-9508-3","article-title":"A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease","volume":"19","author":"Ananthasubramaniam","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12350-010-9288-1","article-title":"Safety of regadenoson in patients with end-stage liver disease","volume":"18","author":"Aljaroudi","year":"2011","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2014.04.004_bib0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results","volume":"1","author":"Cerqueira","year":"2008","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.remn.2014.04.004_bib0100","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1238","article-title":"Acute myocardial infarction during regadenoson myocardial perfusion imaging","volume":"33","author":"Shah","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.remn.2014.04.004_bib0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12350-011-9461-1","article-title":"Seizures associated with regadenoson: a case series","volume":"19","author":"Page","year":"2012","journal-title":"J Nucl Cardiol"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X14000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X14000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T20:28:21Z","timestamp":1538598501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X14000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S2253654X14000900"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2014.04.004","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El regadenos\u00f3n como nuevo agente de estr\u00e9s para la adquisici\u00f3n de im\u00e1genes SPECT de perfusi\u00f3n mioc\u00e1rdica. Experiencia inicial en Holanda","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2014.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and SEMNIM. All rights reserved.","name":"copyright","label":"Copyright"}]}}